American Journal of Cardiovascular Drugs

Hyperuricemia and Adverse Outcomes in Cardiovascular Disease: Potential for Therapeutic Intervention
pp. 309-314(6)
Authors: Gavin A.R.; Struthers A.D.

Clinical Potential of Advanced Glycation End-Product Inhibitors in Diabetes Mellitus
pp. 315-320(6)
Authors: Menè P.; Festuccia F.; Pugliese F.

Immunosuppressive Therapy for Heart Failure: A Guide to Patient Selection
pp. 321-324(4)
Authors: Nowalany-Kozielska E.; Wojnicz R.

The Role of Lipids in the Development of Diabetic Microvascular Complications: Implications for Therapy
pp. 325-338(14)
Authors: Misra A.; Kumar S.; Vikram N.K.; Kumar A.

Smoking Cessation for Patients with Cardiovascular Disease: What is the Best Approach?
pp. 339-349(11)
Authors: Joseph A.M.; Fu S.S.

ACE Inhibition with Moexipril: A Review of Potential Effects Beyond Blood Pressure Control
pp. 351-360(10)
Authors: Pines A.; Fisman E.Z.

Assessment of Anti-Ischemic and Antianginal Effect at Trough Plasma Concentration and Safety of Trimetazidine MR 35mg in Patients with Stable Angina Pectoris: A Multicenter, Double-Blind, Placebo-Controlled Study
pp. 361-369(9)
Authors: Sellier P.; Broustet J-P.

Losartan: In the Reduction of Stroke Risk in Patients with Hypertension and Left Ventricular Hypertrophy
pp. 371-377(7)
Authors: Waugh J.; Keating G.M.

Losartan: A Viewpoint by Sverre E. Kjeldsen
pp. 378-379(2)
Author: Kjeldsen S.E.

Losartan: A Viewpoint by Jorge R. Kizer
pp. 378-379(2)
Author: Kizer J.R.

Spotlight on Abciximab in Patients with Ischemic Heart Disease Undergoing Percutaneous Coronary Revascularization
pp. 381-386(6)
Authors: Ibbotson T.; McGavin J.K.; Goa K.L.